Vise Technologies Inc. purchased a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the 3rd quarter, Holdings Channel reports. The institutional investor purchased 13,916 shares of the medical research company’s stock, valued at approximately $1,201,000.
A number of other institutional investors have also added to or reduced their stakes in the stock. MGO One Seven LLC raised its position in shares of Edwards Lifesciences by 6.1% during the third quarter. MGO One Seven LLC now owns 37,772 shares of the medical research company’s stock valued at $3,260,000 after buying an additional 2,161 shares during the last quarter. State of Wyoming purchased a new position in shares of Edwards Lifesciences in the third quarter worth $131,000. Peak Financial Advisors LLC boosted its position in shares of Edwards Lifesciences by 6.6% during the third quarter. Peak Financial Advisors LLC now owns 42,772 shares of the medical research company’s stock worth $3,692,000 after acquiring an additional 2,641 shares during the last quarter. Soltis Investment Advisors LLC boosted its position in shares of Edwards Lifesciences by 2.4% during the third quarter. Soltis Investment Advisors LLC now owns 6,479 shares of the medical research company’s stock worth $559,000 after acquiring an additional 153 shares during the last quarter. Finally, United Asset Strategies Inc. boosted its position in shares of Edwards Lifesciences by 1.6% during the third quarter. United Asset Strategies Inc. now owns 195,672 shares of the medical research company’s stock worth $16,890,000 after acquiring an additional 3,090 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.
Edwards Lifesciences Stock Up 1.1%
Shares of EW opened at $101.91 on Friday. The stock has a market capitalization of $58.68 billion, a price-to-earnings ratio of 57.58, a price-to-earnings-growth ratio of 2.67 and a beta of 0.85. Edwards Lifesciences Corporation has a 1 year low of $74.66 and a 1 year high of $104.17. The business’s 50 day simple moving average is $88.92 and its 200-day simple moving average is $85.78. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.60 and a quick ratio of 3.77.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The firm had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.68 billion. During the same period in the prior year, the company earned $0.67 EPS. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3.02 earnings per share for the current fiscal year.
Insider Activity at Edwards Lifesciences
In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,045 shares of company stock valued at $451,596 over the last 90 days. 0.31% of the stock is owned by corporate insiders.
Edwards Lifesciences News Roundup
Here are the key news stories impacting Edwards Lifesciences this week:
- Positive Sentiment: Edwards reported Q3 sales growth of 11.2% to $1.72 billion, with adjusted earnings and revenue beating estimates. TMTT sales rose 45.6% and TAVR sales grew 8.8%; the company raised its sales outlook and set adjusted full-year EPS guidance of $2.97–$3.05. Edwards Q3 earnings call highlights
- Positive Sentiment: PROGRESS Trial results found TAVR outperformed active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure outcomes. The findings could support earlier use of the procedure and expand Edwards’ potential market. Trial data points to earlier TAVR use
- Positive Sentiment: Analysts lifted price targets following the results: UBS raised its target to $118 and JPMorgan to $120, while Piper Sandler reaffirmed its buy-equivalent rating with a $115 target. The latest target increases and reaffirmations add to bullish sentiment. UBS reaffirms buy rating Piper Sandler keeps buy rating
- Negative Sentiment: Management has acknowledged that more competition is coming in TAVR, a potential pressure on market share and future growth, although the recent results and trial data provide positive offsets. CEO comments on TAVR competition
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on EW. Mizuho set a $120.00 target price on shares of Edwards Lifesciences in a research note on Thursday. BTIG Research boosted their price target on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday. Rothschild & Co Redburn increased their price objective on shares of Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a report on Monday, July 27th. UBS Group increased their price objective on shares of Edwards Lifesciences from $110.00 to $118.00 and gave the company a “buy” rating in a report on Thursday. Finally, Barclays raised their price objective on Edwards Lifesciences from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $108.88.
Read Our Latest Stock Analysis on EW
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery.
The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Its structural heart portfolio includes transcatheter aortic valve replacement (TAVR) systems and therapies addressing mitral and tricuspid valve disease.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
